Jazz Pharmaceuticals plc

NASDAQ:JAZZ

Biotechnology

Healthcare
$247.77 +0.02%

+$0.05 today

Market cap
$15.90B
Beta
0.33
P/E (TTM)
476.3
EPS (TTM)
$0.48
52W Low $105.00High $243.32

Volume 0.72M

Average 0.92M

JAZZ Weighted Avg Shares (Diluted)

Average shares outstanding including dilutive securities, used to calculate diluted EPS.

Jazz Pharmaceuticals plcNASDAQ: JAZZ

Weighted Avg Shares (Diluted) · Q3 FY2026 · quarter ended Sep 2026

Weighted avg shares (diluted) grows in line with its trailing trend

Q3 FY2026 weighted avg shares (diluted) of 64.7M shares rose 5.0% year over year, behind the +6.5% change in trailing-twelve-month weighted avg shares (diluted). Sequentially, it fell 6.8% from the prior quarter. Over 3 fiscal years it compounded at -0.8% a year.

Context

  • Weighted avg shares (diluted) increased in 1 of the last 3 fiscal years.
  • FY2025 was the lowest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth recovers from +5.0% toward the trailing-twelve-month pace of +6.5%.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterSep 2026
64.7M-6.8% QoQ
Last fiscal yearDec 2025
60.98M-7.6% YoY
LTMSep 2026
65.3M+6.5% YoY
Weighted Avg Shares (Diluted) past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+5.0%——
1 year-7.6%——
3-year CAGR-0.8%——
5-year CAGR——
10-year CAGR——

Weighted Avg Shares (Diluted) history

Shares · from the income statement

Latest · FY2025
60.98M USD
Year-over-year change
-7.6%
4-year CAGR
+0.5%

Weighted Avg Shares (Diluted) vs competitors

How JAZZ compares with its peers on the latest reported figures

  • JAZZ's LTM Sep 2026 weighted avg shares (diluted) of 65.3M shares is the 6th highest of the 9 companies compared; the peer median is 130.99M shares.
  • Its year-over-year change of +6.5% is the 2nd highest of 8, against a peer median of +1.6%.
  • Over three fiscal years its annual growth of -0.8% compares with a peer median of +1.1%.
JAZZ Competitors Peer median
Weighted Avg Shares (Diluted) for JAZZ and competitors
Company Period LTM YoY 3-year CAGR
GMABGenmab A/SLTM Jun 2026637.25M —-1.7%
INCYIncyte CorporationLTM Jun 2026205.31M +3.9%-3.6%
LEGNLegend Biotech CorporationLTM Sep 2026189.27M +2.9%+5.0%
TGTXTG Therapeutics, Inc.LTM Sep 2026158.16M -2.2%+6.0%
NBIXNeurocrine Biosciences, Inc.LTM Sep 2026103.83M +1.6%+1.2%
JAZZJazz Pharmaceuticals plcLTM Sep 202665.3M +6.5%-0.8%
MGNXMacroGenics, Inc.LTM Mar 202663.26M +0.8%+0.9%
HRMYHarmony Biosciences Holdings, Inc.LTM Jun 202658.74M +0.7%-1.4%
LGNDLigand Pharmaceuticals IncorporatedLTM Jun 202620.76M +8.5%+6.4%
Peer median (excluding JAZZ) 130.99M+1.6%+1.1%

Competitors are the stored peer set for JAZZ. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue3.09B3.66B3.83B4.07B4.27B
Cost of Revenue440.76M540.52M435.58M445.71M503.3M
Gross Profit2.65B3.12B3.4B3.62B3.76B
Gross Margin85.8%85.2%88.6%89.0%88.2%
Research & Development505.75M590.45M849.66M884M782.74M
Selling, General & Admin1.45B1.42B1.34B1.39B1.81B
Operating Expenses2.48B3.18B2.82B2.91B3.54B
Depreciation & Amortization552.48M629.47M638.7M660.07M696.3M
EBITDA1.03B1.47B1.45B1.52B262.76M
EBITDA Margin33.2%40.1%37.8%37.4%6.2%
Operating Income170.28M(65.53M)578.58M716.63M224.42M
Operating Margin5.5%-1.8%15.1%17.6%5.3%
Interest Income00000
Interest Expense278.77M288.24M289.44M238.1M195.05M
Other Income / Expenses(283.83M)(317.18M)(283.66M)(247.94M)(853.01M)
Income Before Tax(113.55M)(382.71M)294.92M468.69M(628.59M)
Pre-Tax Margin-3.7%-10.5%7.7%11.5%-14.7%
Income Tax Expense216.12M(158.65M)(119.91M)(91.43M)(272.44M)
Net Income(328.95M)(224.06M)414.83M560.12M(356.15M)
Net Margin-10.6%-6.1%10.8%13.8%-8.3%
EPS (Basic)(5.51)(3.58)6.559.06(5.84)
EPS (Diluted)(5.51)(3.58)6.108.65(5.84)
Weighted Avg Shares59.69M62.54M63.29M61.84M60.98M
Weighted Avg Shares (Diluted)59.69M62.54M72.07M66.01M60.98M

Jazz Pharmaceuticals plc

NASDAQ:JAZZ

Intrinsic Alpha fair value

Locked

Current Price

$247.77

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.